Abstract
Integrins are a family of heterodimeric transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions. They participate in inflammatory reactions mainly by regulation of leukocyte migration, activation and survival. Elevated expression of the cell adhesion molecules, such as VCAM, ICAM and MAdCAM on the lumenal surface of vascular endothelial cells is a critical early event in organ inflammatory processes - including the lung. Adhesive interactions with their counter-receptors on leukocytes, selectins and integrins, result in migration of the leukocytes to the inflammed tissues. Integrins also participate in physiological and pathological reorganization of the lung structure during e.g. pneumonia healing, airway remodeling, angiogenesis, emphysema and pulmonary fibrosis. Agents that could inhibit the function of one or more of these integrins could provide a novel therapeutic strategy targeted to inhibit inflammatory and immune phenomena in the lung.
Keywords: integrins, integrin antagonists, inflammation, bronchial asthma, airway remodeling, emphysema, pulmonary fibrosis
Current Pharmaceutical Design
Title: Integrins in Pulmonary Inflammatory Diseases
Volume: 11 Issue: 7
Author(s): S. Bazan-Socha, A. Bukiej, C. Marcinkiewicz and J. Musial
Affiliation:
Keywords: integrins, integrin antagonists, inflammation, bronchial asthma, airway remodeling, emphysema, pulmonary fibrosis
Abstract: Integrins are a family of heterodimeric transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions. They participate in inflammatory reactions mainly by regulation of leukocyte migration, activation and survival. Elevated expression of the cell adhesion molecules, such as VCAM, ICAM and MAdCAM on the lumenal surface of vascular endothelial cells is a critical early event in organ inflammatory processes - including the lung. Adhesive interactions with their counter-receptors on leukocytes, selectins and integrins, result in migration of the leukocytes to the inflammed tissues. Integrins also participate in physiological and pathological reorganization of the lung structure during e.g. pneumonia healing, airway remodeling, angiogenesis, emphysema and pulmonary fibrosis. Agents that could inhibit the function of one or more of these integrins could provide a novel therapeutic strategy targeted to inhibit inflammatory and immune phenomena in the lung.
Export Options
About this article
Cite this article as:
Bazan-Socha S., Bukiej A., Marcinkiewicz C. and Musial J., Integrins in Pulmonary Inflammatory Diseases, Current Pharmaceutical Design 2005; 11(7) . https://dx.doi.org/10.2174/1381612053381710
DOI https://dx.doi.org/10.2174/1381612053381710 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Association of Low BMI with Aortic Stiffness in Young Healthy Individuals
Current Hypertension Reviews Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Current Vascular Pharmacology Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences Antioxidants in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Foods and Drugs in the Management of Disease: A Case Study Comparing Omega-3 Fatty Acids and Aspirin for Inflammation
Current Pediatric Reviews Fibrinolytic Actinokinase-A Short Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in Exercise Testing
Current Cardiology Reviews Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design